This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and advancing new treatment approaches. As a major recipient of federal research awards, the University of Pittsburgh leverages its academic expertise and research infrastructure to conduct both basic and applied studies addressing national priorities in biomedical sciences, including for the Department of Defense. This grant represents the university's ongoing contributions to the Military Medical Research and Development program's objectives of transforming healthcare for service members and the public through innovative, impactful research.